Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : Tridem Pharma's First Regional Pharmaceutical Distribution Hub in Africa Put into Operation in Côte d'Ivoire

10/20/2021 | 08:11am EST
(Abidjan, Côte d'Ivoire and Shanghai, China, 15 October 2021) On 14 October 2021 Cote d'Ivoire local time, Tridem Pharma SAS, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK) opened a new subsidiary in Abidjan, the capital city of Côte d'Ivoire in West Africa, marking Tridem Pharma's first regional pharmaceutical distribution hub in Africa officially put into operation.

Wu Yifang, Chairman and CEO of Fosun Pharma said, "As an emerging market, Africa has always been Fosun Pharma's priority territory among all the emerging markets worldwide. Fosun Pharma started our Africa business in 2007. The company has established its own marketing team and sales network in Africa since 2009, and in 2017 Fosun Pharma acquired Tridem Pharma. We are glad to announce that, with the opening of Tridem Pharma Cote d'Ivoire, the company's first pharmaceutical distribution hub in francophone Africa that meets EU GDP is now officially put into operation. On behalf of Fosun Pharma, I would like to extend my sincere gratitude to the government of Côte d'Ivoire, for its support to Fosun Pharma and Tridem Pharma to the project. We commit to secure continuous accessibility of pharmaceutical and healthcare products in Africa, and hope that Tridem Pharma's prime service will help to improve the domestic supply capacity of pharmaceutical and healthcare products in Côte d'Ivoire and its neighboring countries. In addition, the distribution hub will be a good source of pharmaceutical and healthcare products quickly responding to public health crises in the region.

Established in 1986, Tridem Pharma is a major player in distribution of pharmaceutical products in Africa. Tridem Pharma joined the Fosun Pharma familiy in 2017. It presents in 35 Africa countries through 9 subsidiaries and 8 branch offices, with 900 employees in Africa, France, China and India. Tridem Pharma's business covers nearly 90% of Africa.

Over the years, pharmaceutical products from outside Africa are transited through France to reach their destinations in French-speaking Africa countries. To help the end users of pharmaceutical and healthcare products in Africa to achieve the goal of "door to door service", Tridem Pharma launched the "PROXY" project since 2019, through which the company plans to establish three regional pharmaceutical distribution hubs in Côte d'Ivoire, Senegal, and Cameroon within 3-5 years, so as to improve local supply of pharmaceutical and healthcare products in most French-speaking Africa countries.

Tridem Pharma's pharmaceutical distribution hub in Côte d'Ivoire is the first professional logistics and distribution platform for pharmaceutical and healthcare products in French-speaking Sub-Saharan Africa. Its first phase has a capacity of 3,300 pallets with a target of 12,000 pallets when completely put into operatioin 2023. By then, the Ivorian distribution hub will be able to directly supply pharmaceutical and healthcare products to all neighbouring countries encluding Ghana and Nigeria.

Tridem Pharma's pharmaceutical distribution hub in Côte d'Ivoire will be a good approach for the continuous accessibility of pharmaceutical and healthcare products in Africa. The distribution hub will help to improve the domestic supply capacity of pharmaceutical and healthcare products in Côte d'Ivoire and its neighboring countries. It will also simplify the drug delivery process and ensure the safety of the supply chain, as well as minimize the risk of medicine shortages in the local market.

In addition, the distribution hub will be a good source of pharmaceutical and healthcare products quickly responding to public health crises in the region. While promoting economic development, the project will also bring local employment opportunities and help to consolidate Côte d'Ivoire's leading role in the pharmceutical industry in West Africa.

Looking forward, Fosun Pharma practices innovation and transformation, integrated operation and steady development, as well as the concept of sustainable development. Fosun Pharma is committed to becoming the first-class enterprise in the global mainstream healthcare industry. In Africa, we will adhere to our 'Booming Africa' strategy, to further expand Tridem Pharma's business network in Africa, so as to make Tridem Pharma a leading distributor of pharmaceutical and healthcare products in Africa.

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 20 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 October 2021 12:10:06 UTC.


© Publicnow 2021
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
11/26SoftBank in investment talks with Chinese mRNA vaccine firm Abogen - sources
RE
11/26SHANGHAI FOSUN PHARMACEUTICAL : Overseas regulatory announcement (h shares)
PU
11/25Fosun Pharma Forms Two Funds to Invest in New Drug-Related Projects
MT
11/24SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement regarding the establishment of inve..
PU
11/24SHANGHAI FOSUN PHARMACEUTICAL : Connected transaction formation of partnership
PU
11/24SHANGHAI FOSUN PHARMACEUTICAL : Revision of annual caps of continuing connected transactio..
PU
11/19China's BioKangtai begins first shipment of AstraZeneca's COVID-19 shot
RE
11/16SHANGHAI FOSUN PHARMACEUTICAL : Notice of the 2021 third extraordinary general meeting
PU
11/16SHANGHAI FOSUN PHARMACEUTICAL : (1) extension of authorisation period and change of author..
PU
11/09Fosun Pharma Unit to Pay $127 Million for 70% Stake in Chinese Medical Institution
MT
More news
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
More recommendations
Financials
Sales 2021 36 399 M 5 703 M 5 703 M
Net income 2021 4 498 M 705 M 705 M
Net Debt 2021 14 452 M 2 264 M 2 264 M
P/E ratio 2021 30,5x
Yield 2021 0,86%
Capitalization 129 B 20 166 M 20 195 M
EV / Sales 2021 3,94x
EV / Sales 2022 3,26x
Nbr of Employees 32 258
Free-Float 58,1%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 52,80 CNY
Average target price 67,38 CNY
Spread / Average Target 27,6%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman